Expects 1H23 operational sales growth lower than 2H in Pharmaceutical and expects Q2 stronger than Q1. Expects "continued competitive growth" in MedTech segment, with 1H23 sales growth lower than 2H. Expects FX to have negative impact on results in 1H23 and "potentially favorable" in 2H23. Expects to complete Consumer Health separation in 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson Reports Earnings: Did it Beat Estimate Forecasts?
- JNJ Gains after Better-than-Expected Q4 Results
- Johnson & Johnson expects some 2022 headwinds to continue in 2023
- Genmab announces 2022 net sales of DARZALEX $7.98B
- Johnson & Johnson sees FY23 adjusted EPS $10.45- $10.65, consensus $10.33